Anti-high mobility group box-1 monoclonal antibody treatment of brain edema induced by influenza infection and lipopolysaccharide.
Identifieur interne : 000A24 ( Main/Exploration ); précédent : 000A23; suivant : 000A25Anti-high mobility group box-1 monoclonal antibody treatment of brain edema induced by influenza infection and lipopolysaccharide.
Auteurs : Nobuyuki Nosaka [Japon] ; Kazuki Hatayama [Japon] ; Mutsuko Yamada [Japon] ; Yousuke Fujii [Japon] ; Masato Yashiro [Japon] ; Hidenori Wake [Japon] ; Hirokazu Tsukahara [Japon] ; Masahiro Nishibori [Japon] ; Tsuneo Morishima [Japon]Source :
- Journal of medical virology [ 1096-9071 ] ; 2018.
Descripteurs français
- KwdFr :
- Animaux, Anticorps monoclonaux (administration et posologie), Facteurs immunologiques (administration et posologie), Femelle, Infections à Orthomyxoviridae (), Japon, Lipopolysaccharides (administration et posologie), Lipopolysaccharides (toxicité), Modèles animaux de maladie humaine, Oedème cérébral (), Oedème cérébral (anatomopathologie), Protéine HMGB1 (antagonistes et inhibiteurs), Protéine HMGB1 (immunologie), Résultat thérapeutique, Souris de lignée BALB C.
- MESH :
- administration et posologie : Anticorps monoclonaux, Facteurs immunologiques, Lipopolysaccharides.
- anatomopathologie : Oedème cérébral.
- antagonistes et inhibiteurs : Protéine HMGB1.
- immunologie : Protéine HMGB1.
- toxicité : Lipopolysaccharides.
- Animaux, Femelle, Infections à Orthomyxoviridae, Japon, Modèles animaux de maladie humaine, Oedème cérébral, Résultat thérapeutique, Souris de lignée BALB C.
- Wicri :
- geographic : Japon.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (administration & dosage), Brain Edema (chemically induced), Brain Edema (pathology), Brain Edema (therapy), Disease Models, Animal, Female, HMGB1 Protein (antagonists & inhibitors), HMGB1 Protein (immunology), Immunologic Factors (administration & dosage), Japan, Lipopolysaccharides (administration & dosage), Lipopolysaccharides (toxicity), Mice, Inbred BALB C, Orthomyxoviridae Infections (complications), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Immunologic Factors, Lipopolysaccharides.
- chemical , antagonists & inhibitors : HMGB1 Protein.
- chemical , toxicity : Lipopolysaccharides.
- geographic : Japan.
- chemically induced : Brain Edema.
- complications : Orthomyxoviridae Infections.
- chemical , immunology : HMGB1 Protein.
- pathology : Brain Edema.
- therapy : Brain Edema.
- Animals, Disease Models, Animal, Female, Mice, Inbred BALB C, Treatment Outcome.
Abstract
Encephalopathy is a major cause of influenza-associated child death and severe neurological sequelae in Japan, highlighting the urgent need for new therapeutic strategies. In this study, we evaluated the effects of anti-high mobility group box-1 monoclonal antibody (α-HMGB1) treatment on brain edema induced by influenza A virus (IAV) and lipopolysaccharide in 4-week-old BALB/c female mice. The results showed that administration of 7.5 mg/kg α-HMGB1 1 h after IAV (A/Puerto Rico/8/34) inoculation significantly alleviated brain edema at 48 h after IAV inoculation, as confirmed by the suppression of Evans Blue dye leakage and matrix metallopeptidase-9 mRNA expression in the brain. Moreover, we also observed suppression of oxidative stress and different cytokines in IAV-inoculated mice. The expression of plasminogen activator inhibitor-1 was also attenuated following treatment with α-HMGB1. Notably, α-HMGB1 treatment had no effect on virus propagation in the lung. In summary, anti-HMGB1 treatment may improve the prognosis in cases with influenza-associated encephalopathy by attenuating brain edema and reducing the inflammatory responses induced by HMGB1.
DOI: 10.1002/jmv.25076
PubMed: 29573352
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000275
- to stream PubMed, to step Curation: 000275
- to stream PubMed, to step Checkpoint: 000293
- to stream Ncbi, to step Merge: 000920
- to stream Ncbi, to step Curation: 000920
- to stream Ncbi, to step Checkpoint: 000920
- to stream Main, to step Merge: 000A25
- to stream Main, to step Curation: 000A24
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti-high mobility group box-1 monoclonal antibody treatment of brain edema induced by influenza infection and lipopolysaccharide.</title><author><name sortKey="Nosaka, Nobuyuki" sort="Nosaka, Nobuyuki" uniqKey="Nosaka N" first="Nobuyuki" last="Nosaka">Nobuyuki Nosaka</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Hatayama, Kazuki" sort="Hatayama, Kazuki" uniqKey="Hatayama K" first="Kazuki" last="Hatayama">Kazuki Hatayama</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Yamada, Mutsuko" sort="Yamada, Mutsuko" uniqKey="Yamada M" first="Mutsuko" last="Yamada">Mutsuko Yamada</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Fujii, Yousuke" sort="Fujii, Yousuke" uniqKey="Fujii Y" first="Yousuke" last="Fujii">Yousuke Fujii</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Yashiro, Masato" sort="Yashiro, Masato" uniqKey="Yashiro M" first="Masato" last="Yashiro">Masato Yashiro</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Wake, Hidenori" sort="Wake, Hidenori" uniqKey="Wake H" first="Hidenori" last="Wake">Hidenori Wake</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Tsukahara, Hirokazu" sort="Tsukahara, Hirokazu" uniqKey="Tsukahara H" first="Hirokazu" last="Tsukahara">Hirokazu Tsukahara</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Nishibori, Masahiro" sort="Nishibori, Masahiro" uniqKey="Nishibori M" first="Masahiro" last="Nishibori">Masahiro Nishibori</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Morishima, Tsuneo" sort="Morishima, Tsuneo" uniqKey="Morishima T" first="Tsuneo" last="Morishima">Tsuneo Morishima</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29573352</idno><idno type="pmid">29573352</idno><idno type="doi">10.1002/jmv.25076</idno><idno type="wicri:Area/PubMed/Corpus">000275</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000275</idno><idno type="wicri:Area/PubMed/Curation">000275</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000275</idno><idno type="wicri:Area/PubMed/Checkpoint">000293</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000293</idno><idno type="wicri:Area/Ncbi/Merge">000920</idno><idno type="wicri:Area/Ncbi/Curation">000920</idno><idno type="wicri:Area/Ncbi/Checkpoint">000920</idno><idno type="wicri:Area/Main/Merge">000A25</idno><idno type="wicri:Area/Main/Curation">000A24</idno><idno type="wicri:Area/Main/Exploration">000A24</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Anti-high mobility group box-1 monoclonal antibody treatment of brain edema induced by influenza infection and lipopolysaccharide.</title><author><name sortKey="Nosaka, Nobuyuki" sort="Nosaka, Nobuyuki" uniqKey="Nosaka N" first="Nobuyuki" last="Nosaka">Nobuyuki Nosaka</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Hatayama, Kazuki" sort="Hatayama, Kazuki" uniqKey="Hatayama K" first="Kazuki" last="Hatayama">Kazuki Hatayama</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Yamada, Mutsuko" sort="Yamada, Mutsuko" uniqKey="Yamada M" first="Mutsuko" last="Yamada">Mutsuko Yamada</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Fujii, Yousuke" sort="Fujii, Yousuke" uniqKey="Fujii Y" first="Yousuke" last="Fujii">Yousuke Fujii</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Yashiro, Masato" sort="Yashiro, Masato" uniqKey="Yashiro M" first="Masato" last="Yashiro">Masato Yashiro</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Wake, Hidenori" sort="Wake, Hidenori" uniqKey="Wake H" first="Hidenori" last="Wake">Hidenori Wake</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Tsukahara, Hirokazu" sort="Tsukahara, Hirokazu" uniqKey="Tsukahara H" first="Hirokazu" last="Tsukahara">Hirokazu Tsukahara</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Nishibori, Masahiro" sort="Nishibori, Masahiro" uniqKey="Nishibori M" first="Masahiro" last="Nishibori">Masahiro Nishibori</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author><author><name sortKey="Morishima, Tsuneo" sort="Morishima, Tsuneo" uniqKey="Morishima T" first="Tsuneo" last="Morishima">Tsuneo Morishima</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama</wicri:regionArea><wicri:noRegion>Okayama</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of medical virology</title><idno type="eISSN">1096-9071</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal (administration & dosage)</term><term>Brain Edema (chemically induced)</term><term>Brain Edema (pathology)</term><term>Brain Edema (therapy)</term><term>Disease Models, Animal</term><term>Female</term><term>HMGB1 Protein (antagonists & inhibitors)</term><term>HMGB1 Protein (immunology)</term><term>Immunologic Factors (administration & dosage)</term><term>Japan</term><term>Lipopolysaccharides (administration & dosage)</term><term>Lipopolysaccharides (toxicity)</term><term>Mice, Inbred BALB C</term><term>Orthomyxoviridae Infections (complications)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps monoclonaux (administration et posologie)</term><term>Facteurs immunologiques (administration et posologie)</term><term>Femelle</term><term>Infections à Orthomyxoviridae ()</term><term>Japon</term><term>Lipopolysaccharides (administration et posologie)</term><term>Lipopolysaccharides (toxicité)</term><term>Modèles animaux de maladie humaine</term><term>Oedème cérébral ()</term><term>Oedème cérébral (anatomopathologie)</term><term>Protéine HMGB1 (antagonistes et inhibiteurs)</term><term>Protéine HMGB1 (immunologie)</term><term>Résultat thérapeutique</term><term>Souris de lignée BALB C</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Immunologic Factors</term><term>Lipopolysaccharides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>HMGB1 Protein</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Lipopolysaccharides</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Japan</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Facteurs immunologiques</term><term>Lipopolysaccharides</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Oedème cérébral</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéine HMGB1</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Brain Edema</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Protéine HMGB1</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>HMGB1 Protein</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Brain Edema</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Brain Edema</term></keywords><keywords scheme="MESH" qualifier="toxicité" xml:lang="fr"><term>Lipopolysaccharides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Female</term><term>Mice, Inbred BALB C</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Femelle</term><term>Infections à Orthomyxoviridae</term><term>Japon</term><term>Modèles animaux de maladie humaine</term><term>Oedème cérébral</term><term>Résultat thérapeutique</term><term>Souris de lignée BALB C</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Japon</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Encephalopathy is a major cause of influenza-associated child death and severe neurological sequelae in Japan, highlighting the urgent need for new therapeutic strategies. In this study, we evaluated the effects of anti-high mobility group box-1 monoclonal antibody (α-HMGB1) treatment on brain edema induced by influenza A virus (IAV) and lipopolysaccharide in 4-week-old BALB/c female mice. The results showed that administration of 7.5 mg/kg α-HMGB1 1 h after IAV (A/Puerto Rico/8/34) inoculation significantly alleviated brain edema at 48 h after IAV inoculation, as confirmed by the suppression of Evans Blue dye leakage and matrix metallopeptidase-9 mRNA expression in the brain. Moreover, we also observed suppression of oxidative stress and different cytokines in IAV-inoculated mice. The expression of plasminogen activator inhibitor-1 was also attenuated following treatment with α-HMGB1. Notably, α-HMGB1 treatment had no effect on virus propagation in the lung. In summary, anti-HMGB1 treatment may improve the prognosis in cases with influenza-associated encephalopathy by attenuating brain edema and reducing the inflammatory responses induced by HMGB1.</div></front></TEI><affiliations><list><country><li>Japon</li></country></list><tree><country name="Japon"><noRegion><name sortKey="Nosaka, Nobuyuki" sort="Nosaka, Nobuyuki" uniqKey="Nosaka N" first="Nobuyuki" last="Nosaka">Nobuyuki Nosaka</name></noRegion><name sortKey="Fujii, Yousuke" sort="Fujii, Yousuke" uniqKey="Fujii Y" first="Yousuke" last="Fujii">Yousuke Fujii</name><name sortKey="Hatayama, Kazuki" sort="Hatayama, Kazuki" uniqKey="Hatayama K" first="Kazuki" last="Hatayama">Kazuki Hatayama</name><name sortKey="Morishima, Tsuneo" sort="Morishima, Tsuneo" uniqKey="Morishima T" first="Tsuneo" last="Morishima">Tsuneo Morishima</name><name sortKey="Nishibori, Masahiro" sort="Nishibori, Masahiro" uniqKey="Nishibori M" first="Masahiro" last="Nishibori">Masahiro Nishibori</name><name sortKey="Tsukahara, Hirokazu" sort="Tsukahara, Hirokazu" uniqKey="Tsukahara H" first="Hirokazu" last="Tsukahara">Hirokazu Tsukahara</name><name sortKey="Wake, Hidenori" sort="Wake, Hidenori" uniqKey="Wake H" first="Hidenori" last="Wake">Hidenori Wake</name><name sortKey="Yamada, Mutsuko" sort="Yamada, Mutsuko" uniqKey="Yamada M" first="Mutsuko" last="Yamada">Mutsuko Yamada</name><name sortKey="Yashiro, Masato" sort="Yashiro, Masato" uniqKey="Yashiro M" first="Masato" last="Yashiro">Masato Yashiro</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A24 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A24 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:29573352
|texte= Anti-high mobility group box-1 monoclonal antibody treatment of brain edema induced by influenza infection and lipopolysaccharide.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:29573352" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a StressCovidV1
| This area was generated with Dilib version V0.6.33. |  |